Race and ethnicity representation in clinical trials: Findings from a literature review of Phase i oncology trials

D. Ross Camidge, Haeseong Park, Karen E. Smoyer, Ira Jacobs, Lauren J. Lee, Zemfira Askerova, Justin McGinnis, Yousef Zakharia

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Aim: To provide an assessment of published literature on the demographic representation in Phase I trials of biopharmaceutical oncology agents. Materials & methods: We conducted a rapid evidence assessment to identify demographic representation reported in Phase I clinical trials for biopharmaceutical oncology agents published in 2019. Results: Globally, the population was predominantly White/Caucasian (62.2%). In the USA, the distribution was heavily skewed toward White/Caucasian (84.2%), with minimal representation of Blacks/African-Americans (7.3%), Asians (3.4%), Hispanics/Latinos (2.8%) or other race/ethnicity groups. Conclusion: Our data highlight that Phase I oncology trials do not reflect the population at large, which may perpetuate health disparities. Further research is needed to understand and address barriers to participation, particularly among under-represented group.

Original languageEnglish
Pages (from-to)3271-3280
Number of pages10
JournalFuture Oncology
Volume17
Issue number24
DOIs
StatePublished - Aug 2021

Keywords

  • Clinical trial
  • Disparities
  • Ethnicity
  • Oncology
  • Phase I
  • Race

Fingerprint

Dive into the research topics of 'Race and ethnicity representation in clinical trials: Findings from a literature review of Phase i oncology trials'. Together they form a unique fingerprint.

Cite this